Bevacizumab biosimilar(Apotex )

贝伐珠单抗生物类似药（Apotex ）

Report date: 2022/03/15 17:48:52

Base Information

Drug NameBevacizumab biosimilar(Apotex )
Drug Alias Name贝伐珠单抗生物仿制药（Apotex ）贝伐单抗生物仿制药（Apotex ）贝伐赛珠单抗生物仿制药（Apotex ）贝伐人源化单抗生物仿制药（Apotex ）BAMBEVI
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsPeritoneal Neoplasms +[5] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsPeritoneal Neoplasms +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCanada
Original Approved Date2021/09/23
Country/TerritoryCanada
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesApotex Inc
China Registration ClassN/A

Develop Information

Active CompaniesApotex Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsPeritoneal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A